Danoprevir

Danoprevir is an orally bioavailable inhibitor of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A, IC50 = 1 nM), a serine protease essential for HCV replication. It is selective for NS3/4A over a panel of 53 proteases at a concentration of 10 µM. Danoprevir inhibits replication of the HCV genotypes 1a, 1b, 4, 5, and 6 (IC50s = 0.2-0.4 nM) as well as 2b and 3a (IC50s = 1.6 and 3.5 nM, respectively) in vitro. It also reduces the number of HCV genotype 1b replicons in Huh-7 cells (EC50 = 1.8 nM).Formal Name: 4-fluoro-1,3-dihydro-2H-isoindole-2-carboxylic acid, (2R,6S,13aS,14aR,16aS)-14a-[[(cyclopropylsulfonyl)amino]carbonyl]-6-[[(1,1-dimethylethoxy)carbonyl]amino]- 1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydro-5,16-dioxocyclopropa[e] pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl ester. CAS Number: 850876-88-9. Synonyms: ITMN-191, R-7227. Molecular Formula: C35H46FN5O9S. Formula Weight: 731.8. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMF:PBS (pH 7.2) (1:4): 0.20 mg/ml, DMSO: 25 mg/ml, Ethanol: 15 mg/ml. SMILES: O=C1N2[C@@](C(N[C@@]3(C(NS(C4CC4)(=O)=O)=O)[C@@H](C3)/C=C\CCCCC[C@@H]1NC(OC(C)(C)C)=O)=O)([H])C[C@@H](OC(N5CC(C(F)=CC=C6)=C6C5)=O)C2. InChi Code: InChI=1S/C35H46FN5O9S/c1-34(2,3)50-32(45)37-27-13-8-6-4-5-7-11-22-17-35(22,31(44)39-51(47,48)24-14-15-24)38-29(42)28-16-23(19-41(28)30(27)43)49-33(46)40-18-21-10-9-12-26(36)25(21)20-40/h7,9-12,22-24,27-28H,4-6,8,13-20H2,1-3H3,(H,37,45)(H,38,42)(H,39,44)/b11-7-/t22-,23-,27+,28+,35-/m1/s1. InChi Key: ZVTDLPBHTSMEJZ-JSZLBQEHSA-N.